The company's proprietary therapeutic approach, Facilitated Allo-HSCT Therapy, is designed to induce immune tolerance by creating chimerism. Chimerism refers to a state in which both the donor’s HSCs and the recipient’s HSCs co-exist in the recipient’s bone marrow.

Talaris maintains corporate offices in Boston, MA, a GMP cell processing facility in Louisville, KY, and research and development laboratories in Houston, TX.